ASCO 2019 —Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC

This article intends to summarize personal highlights from the 2019 ASCO (American Society of Clinical Oncology) Annual meeting. The article does not aim to offer a  comprehensive summary of the 1642 abstracts presented, but rather aims to highlight the abstracts that are the most relevant for the neo/adjuvant therapy of the HER2-negative, HR-positive breast cancer. By doing so, the article generates discussion on the practical implications, while portraying t he rapidly changing landscape of the use of personalized treatment of early breast cancer in patients with HER2-negative, HR-positive disease.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research